Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Growth Potential: How Will Market Size Shift Through 2030?
The deoxyribonucleic acid (dna) sequencing in drug discovery market size has seen swift growth in recent years. It is projected to expand from $8.46 billion in 2025 to $9.49 billion in 2026, at a compound annual growth rate (CAGR) of 12.3%. The market’s historical growth can be attributed to several factors, including increasing investment in genomic research, the expansion of pharmaceutical R&D pipelines, the availability of high-throughput sequencing platforms, a growing focus on personalized medicine, and advancements in sequencing accuracy and speed.
The deoxyribonucleic acid (dna) sequencing in drug discovery market size is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $15.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period is fueled by factors such as the increasing integration of AI-driven genomic analysis, a growing need for targeted treatments, the widening scope of pharmacogenomics applications, more widespread use of sequencing for initial drug screening, and enhanced partnerships between pharmaceutical and biotechnology companies. Key developments expected during this timeframe involve the expanded application of next-generation sequencing for identifying targets, the growing embrace of single-cell sequencing methods, deeper integration of bioinformatics within drug discovery processes, the broadening of precision medicine initiatives, and a heightened emphasis on drug development guided by biomarkers.
Get A Free Sample Report With In-Depth Market Insights:
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Growth Momentum: What Factors Are Shaping Demand?
The increasing need for individualized medicine is anticipated to fuel the expansion of deoxyribonucleic acid (DNA) sequencing within the drug discovery market in the future. Individualized medicine is defined as a medical strategy that customizes disease prevention, diagnosis, and therapy based on a person’s unique genetic composition, way of life, and surrounding elements. This growing demand for personalized medicine largely stems from progress in genomics and molecular diagnostics, facilitating the accurate detection of genetic and molecular distinctions among individuals, thereby enabling customized treatments for enhanced efficacy and fewer adverse reactions. Deoxyribonucleic acid (DNA) sequencing supports personalized medicine through the identification of genetic variations specific to patients, which in turn permits the creation of targeted treatments, better drug choices, and enhanced treatment effectiveness while mitigating negative impacts. For example, data from February 2024, provided by the Personalized Medicine Coalition, a US-based non-profit organization, indicates that in 2023, the Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients, an increase from six in 2022. Among the new personalized treatments approved in 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the increasing need for personalized medicine is propelling the expansion of deoxyribonucleic acid (DNA) sequencing within the drug discovery market.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Segments: Where Is Growth Concentrated?
The deoxyribonucleic acid (dna) sequencing in drug discovery market covered in this report is segmented –
1) By Product Type: Instruments; Consumables
2) By Workflow: Sample Preparation; Sequencing
3) By Technology Type: Sanger Sequencing; Next-Generation Sequencing (NGS)
4) By Application: Drug Discovery; Pharmacogenomics
5) By End-User: Pharmaceutical Companies; Biotechnology Firms
Subsegments:
1) By Instruments: Sequencing Systems; Sample Preparation Systems; Detection And Imaging Systems; Automation And Robotics Systems; Data Analysis Hardware
2) By Consumables: Sequencing Reagents; Library Preparation Kits; Sample Collection Kits; Flow Cells; Quality Control Reagents
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Trends Redefining Industry Growth
Key entities within the deoxyribonucleic acid (DNA) sequencing in the drug discovery market are prioritizing the creation of sophisticated solutions, including high-resolution DNA methylation sequencing assays, aimed at expediting biomarker identification and enhancing precision drug development. These high-resolution DNA methylation sequencing assays represent advanced genomic techniques designed to accurately map DNA methylation at a single-base or near single-base resolution throughout the entire genome. This capability facilitates a thorough assessment of epigenetic alterations influencing gene activity, thereby contributing to a more precise understanding of disease biology and the identification of prospective drug targets. Illustrating this trend, in April 2025, EpiCypher Inc., a US-based epigenetics firm, introduced CUTANA mCUT&RUN and Multiomic CUT&RUN. These two novel DNA methylation sequencing assays were engineered to offer high-resolution methylation profiling while requiring substantially reduced sequencing costs and smaller sample inputs. Such assays empower researchers to concurrently examine DNA methylation and chromatin characteristics, providing deeper multiomic perspectives into the mechanisms governing gene regulation. These technological strides in assays facilitate swifter and more economical target identification and validation, thus accelerating the overall process of drug discovery and development.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Industry Leaders And Competitive Landscape
Major companies operating in the deoxyribonucleic acid (dna) sequencing in drug discovery market are Thermo Fisher Scientific Inc., Eurofins Genomics GmbH, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Genomics, Azenta Life Sciences, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Element Biosciences Inc., Macrogen Inc., Ultima Genomics Inc., SOPHiA GENETICS SA, ProPhase Labs Inc., Singular Genomics Systems Inc., Psomagen Inc., and QitanTech Co Ltd.
View The Full Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report:
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Regional Analysis And Leading Geography
North America was the largest region in the deoxyribonucleic acid (DNA) sequencing in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxyribonucleic acid (dna) sequencing in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
